top of page

Alderley Park, UK – 28 April 2021

Maxwellia, a pioneering British business that is poised to transform the UK’s self care market through its specialist model of making more medicines available to buy from UK pharmacies, has received a £500k investment from the UK Government via conversion of its Government backed ‘Future Fund’ loan into equity giving the British Business Bank a 7.4% stake in the company.

In response to the Covid 19 challenge, the Future Fund was launched as a new £250m initiative unveiled by the Chancellor of the Exchequer, Rishi Sunak, in April last year. Designed to help support UK businesses navigate the challenges presented by the global Covid-19 pandemic, the Future Fund has provided government-backed loans worth between £125,000 and £5 million to innovative businesses. Qualifying criteria required that a half or more employees, of successful companies, are UK-based or that half or more revenues are from UK sales and that the sum loaned at least matched by private investors.

The scheme delivered by the British Business Bank closed at the end of January 2021. As of 20 October 2020, the Future Fund had provided £771 million of funding to 745 companies.


Maxwellia, based at Alderley Park near Manchester, is an established company within the Northern Powerhouse – a government initiative promoting economic growth and talent in the UK‘s great northern cities. Founded in 2013 by Chief Executive Anna Maxwell – a registered pharmacist with over 20 years’ experience – the business specialises solely in ‘switching’, a rigorous process in which prescription only medication is reclassified and made available over the counter.

Maxwellia’s push to convert more prescription medicines to over-the-counter medicines will put pharmacists at heart of nation’s public health, helping futureproof the NHS. The female founded company is, on approval by the regulator, currently poised to create a major step-change in women’s health through a breakthrough launch that finally, after almost 60 years, will enable a widely used prescription only medicine to be be available to buy from local pharmacies.

In addition to the Future Fund, Maxwellia has secured investment from Manchester-based Praetura Ventures, Catapult Ventures, Alderley Park Ventures, BioCity and angel investors in a funding round that closed at £3.28m.

Anna Maxwell says: “We are so proud to be building a new British business in the North West that has innovation at its core and to be a cog in the growth engine of GBplc (Great Britain Limited) that will help us soften the economic impact of the pandemic in time. ‘Switching’ widens access to medicine, supports self care and patient well-being while reducing the burden on public services such as GPs. The government is supportive of encouraging self care and widening access to medicines, as well as promoting the role that pharmacists can play in communities to reduce pressure on the NHS.”

Maxwellia already has three applications under assessment including women’s health products. The company has a robust pipeline of consumer health care brands that it is developing for over-the-counter sale. Maxwellia will use the funding to scale up the manufacture and rollout of its approved drugs, invest in marketing to drive greater consumer awareness on major health conditions and expand its team.



For interview access, images or any further information, please contact:

Reena Bajwa at The Difference Collective: 07956 181688 /

British Pharmaceutical Company Maxwellia Secures Government Future Fund Investment to Spearhead Shift in Self Care

Notes to Editors:



Switching (also termed reclassification) is a rigorous regulatory process facilitating the safe supply of medicines under the supervision of a pharmacist. It is the gold standard for innovation across the global OTC (over the counter) industry where each switch project is unique, intricate and requires precise engineering in order to succeed. Noticing the shortage of exciting OTC innovation, registered pharmacist, founder and CEO Anna Maxwell set up a dedicated operation with a stellar team to build a pipeline of self care innovation that addresses this market challenge.

About Maxwellia

Founded in 2013, Maxwellia is a female founded, British pharma company and the world’s only company completely dedicated to “switching” – prescription-only medicines into versions that can be bought over the counter in a pharmacy. Switching is a rigorous regulatory process enabling pharmacists to safely supply what were previously prescription-only medicines. Maxwellia is developing and commercialising the next-generation of consumer healthcare pharmacy brands treating a range of conditions in major public health categories. It aims to provide people with new ways to conveniently look after themselves by making widely used and effective medicines available over the counter at the pharmacy.

bottom of page